STAT+: Gossamer lung disease drug fails late-stage study, but company will still seek FDA approval

STAT News · Feb 23, 2026 · Collected from RSS

Full Article

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.Gossamer Bio said Monday that its experimental treatment for pulmonary arterial hypertension, a progressive lung disease, failed to achieve the primary goal of a Phase 3 clinical trial. In the study, participants treated for six months with the Gossamer drug, called seralutinib, walked 13 meters further over six minutes compared to participants offered a placebo. The treatment effect favored seralutinib but the difference was not statistically significant. Cough, reported by 37% of seralutinib-treated participants, was the most common side effect. Elevated liver enzymes, a potential risk for liver toxicity, was reported by 13% of patients. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe